Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTUITIVE SURGICAL INCISRG · Entity 2878 | Director | April 23, 2010 | April 23, 2010 |
| MiniMed Group, Inc.MMED · Entity 3758 | Director | October 09, 2026 | October 13, 2026 |
| Outset Medical, Inc.OM · Entity 7026 | Director | June 04, 2026 | June 05, 2026 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | January 04, 2021 | January 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTUITIVE SURGICAL INC
Report date April 23, 2010 · Filed April 23, 2010
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2010-04-23 transaction · row 19
19 source rows · reconciled sequenceRow 1 · 2010-04-23 · Exercise / conversion · Acquired 4,250 · Balance 4,250 Row 2 · 2010-04-23 · Sale · Disposed 200 · Balance 4,050 Row 3 · 2010-04-23 · Sale · Disposed 300 · Balance 3,750 Row 4 · 2010-04-23 · Sale · Disposed 100 · Balance 3,650 Row 5 · 2010-04-23 · Sale · Disposed 400 · Balance 3,250 Row 6 · 2010-04-23 · Sale · Disposed 200 · Balance 3,050 Row 7 · 2010-04-23 · Sale · Disposed 100 · Balance 2,950 Row 8 · 2010-04-23 · Sale · Disposed 200 · Balance 2,750 Row 9 · 2010-04-23 · Sale · Disposed 100 · Balance 2,650 Row 10 · 2010-04-23 · Sale · Disposed 100 · Balance 2,550 Row 11 · 2010-04-23 · Sale · Disposed 300 · Balance 2,250 Row 12 · 2010-04-23 · Sale · Disposed 100 · Balance 2,150 Row 13 · 2010-04-23 · Sale · Disposed 300 · Balance 1,850 Row 14 · 2010-04-23 · Sale · Disposed 100 · Balance 1,750 Row 15 · 2010-04-23 · Sale · Disposed 200 · Balance 1,550 Row 16 · 2010-04-23 · Sale · Disposed 6 · Balance 1,544 Row 17 · 2010-04-23 · Sale · Disposed 104 · Balance 1,440 Row 18 · 2010-04-23 · Sale · Disposed 90 · Balance 1,350 Row 19 · 2010-04-23 · Sale · Disposed 1,350 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.39 · Expires 2019-04-23 | Direct | 0 |
Reported balance
After 2010-04-23 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2010-04-23 · Exercise / conversion · Disposed 4,250 · Balance 0 F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant date.
MiniMed Group, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,684 |
Reported balance
After 2026-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 11,795 · Balance 25,684 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUS. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUS.
Outset Medical, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,585 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,667 · Balance 24,585 F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders |
| Common StockSEC Table I · non-derivative | IndirectGrossman Fam Trust | 12,845 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,845 |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders
ViewRay, Inc.
Report date January 04, 2021 · Filed January 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The D. Keith and Hallie H. Grossman Family Living Trust | 100,855 |
Reported balance
After 2021-01-04 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-01-04 · Grant · Acquired 7,800 · Balance 100,855 F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 4, 2031 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2021 such that 100% of the DSUs will be vested on December 31, 2021, subject to the Reporting Person remaining a service provider through each such vesting date. F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $50,000. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 4, 2031 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2021 such that 100% of the DSUs will be vested on December 31, 2021, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $50,000.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NEVRO CORP
Report date April 03, 2025 · Filed April 03, 2025
Section 16 reporting ended · disclosed 2025-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-03 transaction · row 1
1 source rowRow 1 · 2025-04-03 · Disposition to issuer · Disposed 228,552 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time"). F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated February 6, 2025, by and among the Issuer, Globus Medical, Inc. ("Globus") and Palmer Merger Sub, Inc., a direct, wholly owned subsidiary of Globus ("Merger Sub"), Merger Sub merged with and into the Issuer, and the Issuer became a wholly owned subsidiary of Globus upon consummation of the merger (the "Effective Time").
F2: At the Effective Time, (i) each outstanding share of Common Stock was automatically converted into the right to receive $5.85 in cash (the "Merger Consideration"), (ii) each outstanding award of restricted stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award and (b) the Merger Consideration, and (iii) each outstanding award of performance stock units automatically converted into the right to receive, without interest and subject to withholding taxes, the product of (a) the aggregate number of Common Stock underlying such award, assuming that the applicable performance goals have been achieved at the greater of target and actual level of performance as determined by the compensation committee, and (b) the Merger Consideration.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Disposed 14,137 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 14,137 shares held by the Reporting Person, (i) 11,669 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 2,468 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.49 · Expires 2023-10-23 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-28 · Other · Disposed 18,987 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2024-05-29 | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-28 · Other · Disposed 30,000 · Balance 0 F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, out of the total of 14,137 shares held by the Reporting Person, (i) 11,669 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes (the "Merger Consideration"), and (ii) 2,468 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
F3: This vested option was canceled and converted in the Merger into the right to receive cash equal to the number of shares subject to such option multiplied by the excess, if any, of the Merger Consideration over the exercise price of such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2021 Filed Nov 2, 2021 22:24 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $54.31 | $70,385.76 |
DisclosureSEC source: 0001484612-21-000075 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 6,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 22:24 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 2,592 | $55.00 | $142,560.00 |
DisclosureSEC source: 0001484612-21-000075 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Grossman Fam Trust Disclosed balance after: 7,778 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · ownership.nature: On October 4, 2021, the reporting person filed a Form 4 reporting a sale of 1,234 shares on October 1, 2021. The filing incorrectly reported that the shares were sold from shares held directly by the reporting person, however, the shares were instead sold from shares held indirectly by the reporting person through the Grossman Family Trust. This filing corrects the information in the Form 4 filed on October 4, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:10 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 62 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000066 · edgardoc.xml · derivative · entry 5 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,303 Underlying: Common Stock · 62 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:10 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,234 | $49.69 | $61,317.46 |
DisclosureSEC source: 0001484612-21-000066 · edgardoc.xml · nonDerivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,054 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:10 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 62 | $49.69 | $3,080.78 |
DisclosureSEC source: 0001484612-21-000066 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:10 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 62 | $1.11 | $68.82 |
DisclosureSEC source: 0001484612-21-000066 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2021 Filed Sep 21, 2021 18:05 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,874 | $126.63 | $617,194.62 |
DisclosureSEC source: 0001567619-21-017404 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,964 F1 · balance_after: Includes 63,766 restricted stock units. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · derivative · entry 13 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,365 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · derivative · entry 12 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,661 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · derivative · entry 11 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,957 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · derivative · entry 10 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,253 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $55.00 | $71,280.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 8 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 7 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $55.00 | $71,280.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 6 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 5 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $55.00 | $71,280.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $55.00 | $71,280.00 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| September 17, 2021 Filed Oct 4, 2021 20:08 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000065 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:50 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000056 · edgardoc.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,549 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:50 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $49.17 | $63,721.08 |
DisclosureSEC source: 0001484612-21-000056 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.86 to $49.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 1, 2021 23:50 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000056 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:56 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000054 · edgardoc.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,845 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:56 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $45.00 | $58,320.00 |
DisclosureSEC source: 0001484612-21-000054 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 20:56 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000054 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2021 Filed Aug 17, 2021 11:36 UTC | NEVRO CORP NVRO · Entity 12422 | PurchaseCommon Stock | 7,000 | $105.07 | $735,490.00 |
DisclosureSEC source: 0001567619-21-015958 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,838 F1 · balance_after: Includes 73,025 restricted stock units. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:32 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000039 · edgardoc.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,141 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:32 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $49.23 | $63,804.28 |
DisclosureSEC source: 0001484612-21-000039 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $48.65 to $50.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:32 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000039 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2021 Filed Jun 22, 2021 18:30 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,874 | $160.45 | $782,033.30 |
DisclosureSEC source: 0001567619-21-012498 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,838 F1 · balance_after: Includes 73,025 restricted stock units. Read SEC document |
| June 03, 2021 Filed Jun 4, 2021 20:11 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 3,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-21-000015 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,288 F1 · shares: 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,296 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001484612-21-000013 · edgardoc.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,437 Underlying: Common Stock · 1,296 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:29 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 1,296 | $47.92 | $62,101.86 |
DisclosureSEC source: 0001484612-21-000013 · edgardoc.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $47.47 to $48.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:29 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 1,296 | $1.11 | $1,438.56 |
DisclosureSEC source: 0001484612-21-000013 · edgardoc.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:16 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,592 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0000905148-21-000430 · form4.xml · derivative · entry 6 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,733 Underlying: Common Stock · 2,592 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015, and then in 36 equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:16 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 218 | $59.79 | $13,034.00 |
DisclosureSEC source: 0000905148-21-000430 · form4.xml · nonDerivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $59.77 to $60.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4). Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:16 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 100 | $58.50 | $5,850.00 |
DisclosureSEC source: 0000905148-21-000430 · form4.xml · nonDerivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:16 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 2,274 | $57.87 | $131,603.20 |
DisclosureSEC source: 0000905148-21-000430 · form4.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318 F5 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $57.46 to $58.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:16 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 2,592 | $1.11 | $2,877.12 |
DisclosureSEC source: 0000905148-21-000430 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 11, 2021 Filed Apr 13, 2021 17:34 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,263 | $147.08 | $627,002.04 |
DisclosureSEC source: 0001567619-21-007974 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,712 F1 · balance_after: Includes 82,284 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:02 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,592 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001140361-21-011505 · form4.xml · derivative · entry 4 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,325 Underlying: Common Stock · 2,592 shares Expires 2024-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vested 25% on April 15, 2015, and then in 36 equal monthly installments thereafter. F5 · derivative.expiration_date: This Form 4 corrects the expiration date previously reported as April 16, 2024 on the Form 3 filed on September 14, 2020. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:02 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 2,592 | $55.06 | $142,720.70 |
DisclosureSEC source: 0001140361-21-011505 · form4.xml · nonDerivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $54.78 to $55.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3). Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 13:02 UTC | Outset Medical, Inc. OM · Entity 7026 | Exercise / conversionCommon Stock | 2,592 | $1.11 | $2,877.12 |
DisclosureSEC source: 0001140361-21-011505 · form4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 23, 2021 17:16 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,873 | $142.81 | $695,913.13 |
DisclosureSEC source: 0001567619-21-006807 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,975 F1 · balance_after: Includes 90,382 restricted stock units. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:36 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 20,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-006312 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,848 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on March 11 of each year, beginning March 11, 2022, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 99,642 RSUs. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 13:28 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 7,800 | $6.41 | $49,998.00 |
DisclosureSEC source: 0001209191-21-000636 · doc4.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The D. Keith and Hallie H. Grossman Family Living Trust Disclosed balance after: 100,855 F1 · shares: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's Amended & Restated 2015 Equity Incentive Award Plan or (iii) January 4, 2031 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2021 such that 100% of the DSUs will be vested on December 31, 2021, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $50,000. Read SEC document |
| December 19, 2020 Filed Dec 22, 2020 17:36 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,998 | $181.23 | $905,787.54 |
DisclosureSEC source: 0001567619-20-021500 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,895 F1 · balance_after: Includes 78,689 restricted stock units. Read SEC document |
| September 19, 2020 Filed Sep 22, 2020 17:38 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 4,998 | $142.50 | $712,215.00 |
DisclosureSEC source: 0001567619-20-016985 · doc1.xml · nonDerivative · entry 1 GROSSMAN D KEITH · CIK 0001218702 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,893 F1 · balance_after: Includes 87,948 restricted stock units. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 00:20 UTC | Outset Medical, Inc. OM · Entity 7026 | ConversionSeries D Redeemable Convertible Preferred Stock · Derivative | 32,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-020791 · form4.xml · derivative · entry 3 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The D. Keith and Hallie H. Grossman Family Living Trust Disclosed balance after: 0 Underlying: Common Stock · 5,372 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F3 · derivative.exercise_date: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F3 · derivative.expiration_date: The Series D redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series D redeemable convertible preferred stock converted into approximately 0.1671 Shares. These shares had no expiration date. F1 · ownership.direct: These shares of common stock of the Issuer ("Shares") are held directly by The D. Keith and Hallie H. Grossman Family Living Trust, for which the reporting person and his spouse serve as trustees. F1 · ownership.nature: These shares of common stock of the Issuer ("Shares") are held directly by The D. Keith and Hallie H. Grossman Family Living Trust, for which the reporting person and his spouse serve as trustees. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 00:20 UTC | Outset Medical, Inc. OM · Entity 7026 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 38,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-020791 · form4.xml · derivative · entry 2 GROSSMAN D KEITH · CIK 0001218702 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The D. Keith and Hallie H. Grossman Family Living Trust Disclosed balance after: 0 Underlying: Common Stock · 4,885 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F2 · derivative.exercise_date: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F2 · derivative.expiration_date: The Series C redeemable convertible preferred stock automatically converted into Common Stock upon the closing of the IPO. Each share of Series C redeemable convertible preferred stock converted into approximately 0.1266 Shares. These shares had no expiration date. F1 · ownership.direct: These shares of common stock of the Issuer ("Shares") are held directly by The D. Keith and Hallie H. Grossman Family Living Trust, for which the reporting person and his spouse serve as trustees. F1 · ownership.nature: These shares of common stock of the Issuer ("Shares") are held directly by The D. Keith and Hallie H. Grossman Family Living Trust, for which the reporting person and his spouse serve as trustees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.